Detection and in vitro metabolism of AOD9604 Cox 2015 Drug Testing and Analysis Wiley Online Library The FDA has repeatedly flagged AOD 9604 as a compound of concern. It was placed on the Category 2 list in 2023 bulk drug substances in compounding that may present significant The effects of 14 day infusion of saline (control), AOD9604 (250 Download Scientific Diagram The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Watson responsible for AOD 9604 use, says WADA boss Fahey AOD9604 Wikipedia